BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37545411)

  • 1. Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma.
    Lin Z; Xu H; Ma J; Ma Y; Li Q; Kang H; Zhang M; Chen B
    Hematology; 2023 Dec; 28(1):2243424. PubMed ID: 37545411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
    J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
    David KA; Sundaram S; Kim SH; Vaca R; Lin Y; Singer S; Malecek MK; Carter J; Zayac A; Kim MS; Reddy N; Ney D; Habib A; Strouse C; Graber J; Bachanova V; Salman S; Vendiola JA; Hossain N; Tsang M; Major A; Bond DA; Agrawal P; Mier-Hicks A; Torka P; Rajakumar P; Venugopal P; Berg S; Glantz M; Goldlust SA; Folstad M; Kumar P; Ollila TA; Cai J; Spurgeon S; Sieg A; Cleveland J; Chang J; Epperla N; Karmali R; Naik S; Martin P; Smith SM; Rubenstein J; Kahl B; Evens AM
    Am J Hematol; 2023 Jun; 98(6):900-912. PubMed ID: 36965007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
    Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
    Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
    Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
    Salamoon M; Hussein T; Kenj M; Bachour M
    Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
    J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
    Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
    J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
    Wang XX; Huang HQ; Bai B; Cai QQ; Cai QC; Gao Y; Xia YF; Xia ZJ; Jiang WQ
    Leuk Lymphoma; 2014 Nov; 55(11):2497-501. PubMed ID: 24605911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
    Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
    Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
    J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
    Faivre G; Butler MJ; Le I; Brenner A
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):665-669. PubMed ID: 31351990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
    Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
    Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.